$KZR
Kezar Life Sciences, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019009369 Filed on March 26, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.380M $6.590M $780.0K
YoY Change 57.62% 189.04%
% of Gross Profit
Research & Development $5.927M $18.14M $1.640M
YoY Change 65.93% 180.35%
% of Gross Profit
Depreciation & Amortization $303.0K $690.0K $50.00K
YoY Change 248.28% 294.29%
% of Gross Profit
Operating Expenses $8.309M $24.73M $2.419M
YoY Change 63.37% 182.62%
Operating Profit -$8.309M -$24.73M
YoY Change 63.37% 182.62%
Interest Expense $667.0K $1.559M $120.0K
YoY Change 379.86% 571.98%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.640M -$23.17M -$2.300M
YoY Change 54.34% 171.95%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.642M -$23.17M -$2.300M
YoY Change 54.48% 172.01%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$401.3K -$2.258M -$125.5K
COMMON SHARES
Basic Shares Outstanding 19.12M
Diluted Shares Outstanding 19.04M 10.26M

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $101.1M $107.4M
YoY Change 114.65% 110.59%
Cash & Equivalents $18.47M $24.20M $51.03M
Short-Term Investments $82.70M $83.30M
Other Short-Term Assets $991.0K $2.400M $508.0K
YoY Change -64.61% 200.0%
Inventory
Prepaid Expenses $1.664M $785.0K
Receivables
Other Receivables
Total Short-Term Assets $103.8M $109.8M $52.33M
YoY Change 106.34% 109.94%
LONG-TERM ASSETS
Property, Plant & Equipment $4.846M $4.600M $1.540M
YoY Change 34.61% 206.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $282.0K $300.0K $343.0K
YoY Change -6.0% -25.0%
Total Long-Term Assets $9.267M $4.900M $1.896M
YoY Change 131.68% 157.89%
TOTAL ASSETS
Total Short-Term Assets $103.8M $109.8M $52.33M
Total Long-Term Assets $9.267M $4.900M $1.896M
Total Assets $113.1M $114.7M $54.22M
YoY Change 108.21% 111.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.448M $200.0K $547.0K
YoY Change 106.86% -60.0%
Accrued Expenses $2.406M $2.700M $911.0K
YoY Change -29.24% 200.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.758M $3.300M $1.484M
YoY Change 1.23% 120.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.200M $2.500M
YoY Change 195.24% 400.0%
Total Long-Term Liabilities $6.200M $2.500M
YoY Change 195.24% 400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.758M $3.300M $1.484M
Total Long-Term Liabilities $6.200M $2.500M
Total Liabilities $10.91M $5.900M $1.978M
YoY Change 60.46% 195.0%
SHAREHOLDERS EQUITY
Retained Earnings -$56.84M -$26.03M
YoY Change
Common Stock $159.1M $452.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $102.1M $108.8M -$25.69M
YoY Change
Total Liabilities & Shareholders Equity $113.1M $114.7M $54.22M
YoY Change 108.21% 111.62%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$7.642M -$23.17M -$2.300M
YoY Change 54.48% 172.01%
Depreciation, Depletion And Amortization $303.0K $690.0K $50.00K
YoY Change 248.28% 294.29%
Cash From Operating Activities -$6.700M -$20.79M -$1.620M
YoY Change 77.91% 156.41%
INVESTING ACTIVITIES
Capital Expenditures $34.00K $1.120M -$60.00K
YoY Change -82.56% 187.92%
Acquisitions
YoY Change
Other Investing Activities $1.010M -$82.78M
YoY Change
Cash From Investing Activities $976.0K -$83.90M -$60.00K
YoY Change -600.51% 21469.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $77.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.000K 77.91M 0.000
YoY Change -84.0% 56.59%
NET CHANGE
Cash From Operating Activities -6.700M -20.79M -1.620M
Cash From Investing Activities 976.0K -83.90M -60.00K
Cash From Financing Activities 4.000K 77.91M 0.000
Net Change In Cash -5.712M -26.86M -1.680M
YoY Change 44.68% -165.07%
FREE CASH FLOW
Cash From Operating Activities -$6.700M -$20.79M -$1.620M
Capital Expenditures $34.00K $1.120M -$60.00K
Free Cash Flow -$6.734M -$21.91M -$1.560M
YoY Change 70.01% 157.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1993000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
39000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8478000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
599291
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-150000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-26.56
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.21
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23259000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-8990000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10264584
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-8416000
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19114421
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19114421
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18136000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6469000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7373000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6590000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2280000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1617000
CY2017 us-gaap Operating Expenses
OperatingExpenses
8749000
CY2016 us-gaap Operating Expenses
OperatingExpenses
8990000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-8990000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
948578
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19118421
CY2018Q2 dei Entity Public Float
EntityPublicFloat
267000000
CY2018 us-gaap Operating Expenses
OperatingExpenses
24726000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-24726000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-8749000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1559000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
232000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-8517000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24182000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51033000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
83250000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1884000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
785000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
489000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
508000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
109805000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
52326000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
13000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4595000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1540000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
343000
CY2018Q4 us-gaap Assets
Assets
114682000
CY2017Q4 us-gaap Assets
Assets
54222000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
193000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
547000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2678000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
911000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
354000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
112000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3337000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1484000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2548000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
494000
CY2018Q4 us-gaap Liabilities
Liabilities
5885000
CY2017Q4 us-gaap Liabilities
Liabilities
1978000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
77931000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158176000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
451000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-203000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-111000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49195000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26028000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
108797000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-25687000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114682000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54222000
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
75533240
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12263126
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12263126
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
96000000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.26
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
338446
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9140000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
948578
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-23167000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-72000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-92000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
128000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-17428000
CY2017 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Common Shares Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToCommonSharesIssuedPursuantToEarlyExercises
16000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
203000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
77931000
CY2018 kzr Issuance Of Common Stock Initial Public Offering
IssuanceOfCommonStockInitialPublicOffering
77695000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2018 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Common Shares Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToCommonSharesIssuedPursuantToEarlyExercises
69000
CY2018 us-gaap Profit Loss
ProfitLoss
-23167000
CY2017 us-gaap Profit Loss
ProfitLoss
-8517000
CY2016 us-gaap Profit Loss
ProfitLoss
-8990000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
690000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
175000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
154000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1993000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
203000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
128000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
476000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-106000
CY2018 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1136000
CY2017 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
543000
CY2016 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
598000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-61000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
282000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1440000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
844000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-469000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-8000
CY2017 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
6000
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
295000
CY2017 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-5000
CY2016 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-15000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20792000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8109000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9760000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1120000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
389000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
119244000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36450000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83904000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-389000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-132000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
77695000
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
49755000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
218000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
36000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77913000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49755000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-81000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29000
CY2016 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-150000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26864000
CY2018 kzr Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
77931000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41286000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10006000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51046000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9760000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19766000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24182000
CY2018 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
69000
CY2017 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
16000
CY2018 kzr Addition Of Tenant Improvement Paid By Landlord
AdditionOfTenantImprovementPaidByLandlord
2703000
CY2017 kzr Addition Of Tenant Improvement Paid By Landlord
AdditionOfTenantImprovementPaidByLandlord
464000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.54
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the useful lives of fixed assets, stock-based compensation, and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</p>
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
422000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
224000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1213010
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The majority of the Company&#8217;s cash, cash equivalents and marketable securities are held by financial institutions in the United States, while approximately $1.0 million is held by a financial institution in Australia. Such deposits in the United States may be in excess of insured limits. </p>
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1121901
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
142528
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10917
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2181466
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
833679
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.54
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.93
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
83250000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
83250000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-5.62
CY2018 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1779
CY2018Q2 kzr Stockholders Equity Note Minimum Price Post Split
StockholdersEquityNoteMinimumPricePostSplit
15.884
CY2018Q2 kzr Stockholders Equity Note Adjusted Price Post Split
StockholdersEquityNoteAdjustedPricePostSplit
7.942
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9747000
CY2016Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
13000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
5000
CY2017 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
499000
CY2016 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
385000
CY2018Q4 kzr Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
5000
CY2017Q4 kzr Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
498000
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018Q4 kzr Operating Lease Expected Liabilities To Recognize
OperatingLeaseExpectedLiabilitiesToRecognize
7100000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4200000
CY2018Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
2900000
CY2018Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
83270000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
83270000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5530000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1895000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
935000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
355000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
1881000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
2192000
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.90
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
2257000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.038
CY2018Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1146000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.020
CY2017Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
108000
CY2018Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
434000
CY2017Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
340000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
736000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.014
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.80
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.314
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.00
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.292
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.068
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.00
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.395
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1009000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
169000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
20000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
999000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10985000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6802000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6607000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1194000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
515000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
453000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13188000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
370000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43189000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18008000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1993000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
203000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
128000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3981000
CY2018 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q3 kzr Operating Lease Area
OperatingLeaseArea
24357
CY2017Q3 kzr Lease Commenced Date
LeaseCommencedDate
2018-03-01
CY2017Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-02-28
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1453000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1497000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1542000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1588000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1635000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1966000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
9681000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 kzr Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
0
CY2015Q4 kzr Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax
ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax
250000
CY2018 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
175000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.060
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.005
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12560000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7434000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
628000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
52000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
44000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
628000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7036000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6775000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7486000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7080000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-5663000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
52000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
44000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3600000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5100000
CY2018 kzr Period For Change In Ownership Percentage For Operating Loss Carryforward
PeriodForChangeInOwnershipPercentageForOperatingLossCarryforward
P3Y
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018Q4 kzr Liability Related To Uncertain Tax Position
LiabilityRelatedToUncertainTaxPosition
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2270723
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-5782000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10264584
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
599291
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
338446
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7132205
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13714754
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.53
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.31
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
6950000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
6264000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
6426000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-4947000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5086000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
2419000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2257000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1880000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2080000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-2300000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.43
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.30
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.31
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.34

Files In Submission

Name View Source Status
0001564590-19-009369-index-headers.html Edgar Link pending
0001564590-19-009369-index.html Edgar Link pending
0001564590-19-009369.txt Edgar Link pending
0001564590-19-009369-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
guv251ib2xvo000001.jpg Edgar Link pending
guv251ib2xvo000002.jpg Edgar Link pending
guv251ib2xvo000003.jpg Edgar Link pending
guv251ib2xvo000004.jpg Edgar Link pending
guv251ib2xvo000005.jpg Edgar Link pending
guv251ib2xvo000006.jpg Edgar Link pending
guv251ib2xvo000007.jpg Edgar Link pending
guv251ib2xvo000008.jpg Edgar Link pending
guv251ib2xvo000009.jpg Edgar Link pending
guv251ib2xvo000010.jpg Edgar Link pending
guv251ib2xvo000011.jpg Edgar Link pending
guv251ib2xvo000012.jpg Edgar Link pending
guv251ib2xvo000013.jpg Edgar Link pending
guv251ib2xvo000014.jpg Edgar Link pending
kzr-10k_20181231.htm Edgar Link pending
kzr-20181231.xml Edgar Link completed
kzr-20181231.xsd Edgar Link pending
kzr-20181231_cal.xml Edgar Link unprocessable
kzr-20181231_def.xml Edgar Link unprocessable
kzr-20181231_lab.xml Edgar Link unprocessable
kzr-20181231_pre.xml Edgar Link unprocessable
kzr-ex1013_404.htm Edgar Link pending
kzr-ex231_149.htm Edgar Link pending
kzr-ex311_150.htm Edgar Link pending
kzr-ex312_151.htm Edgar Link pending
kzr-ex321_152.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending